Dr. DuBois holds dual roles as director of MUSC Hollings Cancer Center, an appointment he began in August 2020, and as dean of the College of Medicine, a position he has held since he joined MUSC in 2016. As a physician-scientist, Dr. DuBois is passionate about cancer research and patient-centered care and his expertise guides Hollings forward in both areas. An international leader in the cancer community, Dr. DuBois has more than 30 years of research experience and over 20 years of concurrent leadership experience, including senior roles at MD Anderson Cancer Center and Vanderbilt-Ingram Cancer Center. He was elected to the National Academy of Medicine in 2019, which places him in the company of an elite group of internationally renowned scientists and doctors.
Dr. Yu is a professor with a primary appointment in Department of Microbiology & Immunology and a secondary in the division of Hematology/Oncology in the Department of Medicine, where he holds a SmartState Endowed Chair in Cancer Stem Cell Biology and Therapy. In this director role, Dr. Yu identifies and shapes the trajectory of new scientific directions and integrates basic science discoveries across multiple discipline areas helping to accelerate translational advances into the clinic.
A Professor of Public Health Sciences, Dr. Ford oversees the Center’s effort to address the state’s critical cancer disparities while implementing initiatives that integrate the expertise in population sciences among the Center’s cancer control researchers. Through community outreach and educational programs, Dr. Ford and her team work with minority leaders throughout the state to build bi-directional, trusting, and long-lasting partnerships, which are critical to Hollings investigators in tailoring culturally and contextually knowledgeable cancer interventions. She also works with the South Carolina Department of Health and Environmental Control to implement cancer-focused initiatives, including the State Cancer Plan.
Dr. Mahvi serves as the Chief of the Oncology Integrated Center of Clinical Excellence (ICCE) and Chief of Surgical Oncology. In his leadership role, Dr. Mahvi oversees the clinical activities and performance of the Hollings Cancer Center. In coordination with MUSC leadership, faculty, physicians and staff, Dr. Mahvi executes strategies for program development, growth and patient access as well as managing the financial efforts of clinical operations.
Dr. Rosenzweig is a Professor of Cell & Molecular Pharmacology. As Associate Director, he oversees the ongoing evaluation, development and growth of Hollings-supported shared research resources. These shared facilities provide access to critical technologies, services and consultation that enhance scientific interaction and productivity of cancer center members.
Dr. Guttridge joined MUSC in 2018 as the Hollings Cancer Center Associate Director of Translational Science and the Director of the Charles P. Darby Children’s Research Institute. Dr. Guttridge holds a robust research funding portfolio and has authored more than 130 peer-reviewed publications. He has received numerous recognitions for his contributions to cancer research and his dedication to fostering multidisciplinary and collaborative science.
Dr. Lilly is a professor in the Department of Medicine and a medical oncologist in the Division of Hematology/Oncology at MUSC. A seasoned clinical trialist with a robust portfolio of investigator initiated trials, Dr. Lilly is charged with facilitating the efforts to bring scientific discoveries emanating from Hollings scientific laboratories into clinical application through clinical trials.
Dr. Hughes-Halbert is a Professor of Psychiatry and Behavioral Sciences. As Associate Director, she ensures the education and training opportunities for pre- and post-doctoral students as well as junior faculty within the Hollings Cancer Center are well-structured, coordinated across multiple initiatives, effective, and promote transdisciplinary collaborations.